cyrilzakka/clinical-trials huggingface dataset:
Safety and Efficacy of Autologous Stem Cell Therapy in Chronic Stroke

The purpose of this study was to study the safety and effect of stem cell therapy on the functional recovery in patients with chronic stroke.


Eligibility Criteria:
Inclusion Criteria:

* males and females
* above 18 years of age
* diagnosed as stroke by clinical and MRI findings

Exclusion Criteria:

* presence of respiratory distress
* presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus
* malignancies
* acute medical conditions such as respiratory infection, fever
* hemoglobin less than 8
* bleeding tendency
* bone marrow disorder
* left ventricular ejection fraction \< 30%
* pregnancy or breastfeeding
Mulligan SNAG Technique in Individuals With Lumbar Intervertebral Disc Protrusion

This study aimed to examine the effects of the Mulligan SNAG mobilization technique, applied in addition to conventional physiotherapy on the structure of the intervertebral disc and physical functioning in patients diagnosed with low back pain due to lumbar intervertebral disc protrusion. 38 volunteer patients will participate in the study. The participants will be randomized as an interventional and control gropus.

Participants will be treated 3 days a week for 4 weeks. The session duration will be 40-45 minutes. Visual analog scale-VAS, oswestry disability index, magnetic imaging-MRI assessment, functıonal independence scale-FIM, Tampa kinesiophobia scale, one leg stand test, sit-stand test, 10-meter walking test, cadence , Nottingham health profile will be used to assses the participants in the two groups. All participants will be evaluated in the 5th week of the study. The program includes physical therapy session (Hot packed, trans cuteneal electric stimulation, therapeutic ultrasound, and therapautic exercises) and the Mulligan SNAG mobilization technique.

Eligibility Criteria:
Inclusion Criteria:

1. Being between the ages of 20-60
2. Those diagnosed with lumbar intervertebral disc heniation (protrusion on L1-L2, L2-L3, L3-L4, L4-L5, L5-S1) at a single level
3. Those who voluntarily agreed to participate in the study

Exclusion Criteria:

* Individuals diagnosed with Lumbar Bulging, Extruded, Sequestered discs
* Individuals who have undergone lumbar region spinal surgery
* Individuals with spinal deformity (scoliosis, spondylolisthesis, Ankylosing Spondylitis)
* Individuals with lumbar stenosis
* Pregnant women
* Individuals receiving treatment for malignancy (primary or metastatic tumoral conditions in the lumbar region)
* Individuals diagnosed with advanced osteoporosis
* Individuals diagnosed with discitis
The Effects of Sex, Body Mass Index, Day-to-Day Subject Variability for the ProLung Test and Variability of a Single Device When Volume-Averaged Thoracic Bioconductance is Measured With the ProLung Test

Assess the repeatability of the ProLung Test

This repeatability study of the ProLung Test enrolled sixty subjects, 30 male and 30 female, half of each sex with a body mass index (BMI) of 30 or more, and half with a BMI of 28 or less. Each subject was scanned twice on Day One and twice on Day Two. All scans were done by the same operator on the same device. Fifty-nine subjects produced evaluable data. Four models (algorithms) were tested.

Eligibility Criteria:
Inclusion Criteria:

* Age 35 to 70 years
* Able to understand and fulfill all requirements of this protocol
* Provide signed informed consent

Exclusion Criteria:

* Pacemaker or other implanted medical device
* Current life-threatening medical condition
* Current or recent use of systemic corticosteroids
* Pregnant or lactating
* Unusually strenuous exercise within previous 24 hours
* Current abuse of alcohol or drugs
* Medical or anatomical condition that precludes testing of all 62 measurement points
* Other condition or reason at the discretion of the Principal Investigator or medical monitor
Treatment of Knee Arthrosis With Platelet-derived Growth Factors vs. Hyaluronic Acid.

Primary aim of this trial was to assess efficacy three intraarticular injections of platelet lysate when compared to hyaluronic acid. Additional objectives were to compare the treatment groups in terms of a number of functional scales and of number of adverse events.

Intra-articular injections of hyaluronic acid are effective in improving symptoms and slow disease progression, but are not able to revert the damage mechanism and trigger cartilage healing.

Growth factors included in PRP could stimulate cartilage repair, normalize synovial fluid viscoelasticity, induce a correction in tissue damage, improve articular function, control pain and ameliorate quality of life.

Primary aim of this trial was to assess, among patients with grade II/III osteoarthrosis of the knee, efficacy (as determined by improvement at MRI 6 months after the first injection) of three intraarticular injections of platelet lysate when compared to hyaluronic acid. Additional objectives were to compare the treatment groups in terms of a number of functional scales (WOMAC, Lysholm, Tegner Knee, Scale, AKS, Lequesne, VAS) and of number of adverse events.

Eligibility Criteria:
Inclusion Criteria:

* grade II/III OA of the knee demonstrated at MRI17,18, according to Shahriaree Classification System - modified
* no previous OA treatment with local hyaluronic acid or steroid injections
* ife expectancy \>1 year
* no ongoing pregnancy
* ability to understand and complete clinical and functional scales Lysholm, WOMAC, AKS, VAS
* written consent.
Neutrophil/Lymphocyte (N/L) Ratio and Long Term Follow-up in ST-elevation Myocardial Infarction

Although the pre-procedural neutrophil to lymphocyte ratio (N/L) has been associated with adverse outcomes among patients with coronary artery disease, its role during the acute phase of ST-segment elevation myocardial infarction (STEMI) has not been fully investigated. This study sought to investigate the association of the pre-procedural N/L ratio within-hospital and long-term outcomes among STEMI patients undergoing primary percutaneous coronary intervention (PCI).

Inflammation plays a role in the initiation and progression of the atherosclerotic process. Due to a growing recognition of its role, recent studies have focused on inflammatory markers and their association with outcomes in patients with ST-segment elevation myocardial infarction (STEMI). Recently, our single center study demonstrated that preprocedural neutrophil/lymphocyte (N/L) ratio is an independent predictor of impaired coronary flow after primary percutaneous coronary intervention (PCI) and of in-hospital major advanced cardiac events (MACE) in patients with STEMI.Several previous studies also evaluated the role of N/L ratio in long-term outcomes among patients with STEMI; however, they evaluated the association between long-term mortality and in-hospital N/L ratio, they were single-center studies and they evaluated a relatively small study population.

In the present multicenter experience, the investigators aimed to investigate the association of the preprocedural N/L ratio with the in-hospital and long-term outcomes in patients with STEMI undergoing primary PCI.

Eligibility Criteria:
Inclusion Criteria:

ST elevated myocardial infarction

Exclusion Criteria:

Treatment with fibrinolytic drugs in the previous 24 hours Active infection Previously documented history of a systemic inflammatory process Known malignancy End-stage liver disease Renal failure
Patient-controlled Sedation Versus Target-controlled Infusion in Orthopaedic Surgery Under Central Neuraxial Block

Orthopaedic surgeries involving the legs can be done under nerve block, where patients will be numb of pain at the operated site but awake during surgery. Sedation can be given to allay anxiety and provide comfort throughout the surgery. Sedation can be given by the anaesthetic doctors by using target-comtrolled infusion pump, or self-administered by patients by means of specialised machines. This study compares two method of administration of sedation, patient-controlled sedation (PCS) versus target-controlled infusion sedation (TCIS) by anaesthetic doctors, in people undergoing orthopaedic surgeries under nerve block.

Central neuraxial block (CNB) is one of the mainstays of anaesthesia methods in various disciplines particularly orthopaedic surgeries. However the state of consciousness can potentially cause patient anxiety thus sedation is often utilized as a mean to improve patient satisfaction and increase patient acceptance of CNB.

Conventionally, the anaesthesiologist administers sedatives for the patients. Propofol is the commonly used drug for sedation due to its favourable pharmacokinetic profile, which results in fast induction, easy control of depth of sedation and rapid recovery. It can be infused by using target-controlled infusion (TCI) devices where the anaesthetists titrates propofol by setting desired target plasma and effect site concentration. However it is difficult to judge precisely patient requirements for adequate patient sedation, comfort and analgesia as patients' needs differ.

Patient-controlled sedation (PCS) is a valid option, initially adapted from post surgery patient-controlled analgesia. It allows patients to titrate sedative medication to their comfort and therefore present an option that addresses the needs of patients with strong desire to maintain sense of control during procedures.

This study was designed to compare total propofol requirement between PCS versus TCI sedation (TCIS), complications and patient satisfaction, in patients undergoing lower limb orthopaedic surgery under CNB.

Eligibility Criteria:
Inclusion Criteria:

1. American Society of Anesthesiologists (ASA) I or II.
2. Aged 18-65 years.
3. Elective lower limb orthopaedic surgery under CNB anticipated to last for 1.5 to 2 hours

Exclusion Criteria:

1. Body Mass Index (BMI) \> 30kg/m2
2. Unable to cooperate (eg. mental disorders, language barrier)
3. Drug abuse
4. Alcoholism (chronic daily alcohol intake greater than 75 g of pure alcohol for ≥ 2 years, where 75g of alcohol = 5 cans of beer, 1 bottle of wine or half a pint of distilled spirit)
5. Contraindications to the study drugs
6. Pregnancy
7. Significant pulmonary or cardiovascular diseases, including obstructive sleep apnoea and obesity hypoventilation syndrome
8. Features of difficult airway
Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF)

To access the efficacy of intravenous (IV) administration of CD-NP on changes in cardiac output and wedge pressure in patients with stabilized acute heart failure


Eligibility Criteria:
Key Inclusion Criteria:

* Hospitalization for AHF
* In need of hemodynamic monitoring

Key Exclusion Criteria:

* Administration of intravenous radiographic contrast agent within 7 days prior to screening or planned IV contrast media administration in the 4 days after screening or acute contrast-induced nephropathy at the time of screening
* Current or planned treatment with any IV therapies, including diuretics, vasodilators (including nesiritide), vasopressin antagonists, positive inotropic agents and vasopressors, or mechanical support
* Current or planned ultrafiltration, hemofiltration, or dialysis within 7 days of screening
* Significant pulmonary disease
* Known valvular heart disease
* Any organ transplant recipient or patient currently listed for transplant or admitted for any transplantation.
* Major surgery within 30 days of screening
* Other major disability or disease with expected survival less than 6 months.
* Major neurologic event, including cerebrovascular events, in the 60 days prior to screening
* Clinical diagnosis of acute coronary syndrome within 45 days of screening
* Troponin T ≥ 3 times the upper limit of normal at screening
* Significant arrhythmias
* Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy
* Liver function abnormality
* Administration of an investigational drug or implantation of investigational device, or participation in another trial, within 30 days prior to screening
Mechanism of Action of Ocrelizumab in Multiple Sclerosis

Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.

The study will investigate immune cell subsets, and how the cells are modified by this therapy over a 1-year period in 25 subjects. Blood will be drawn at baseline, 2 weeks, 6 mo, and 12 mo.

Immune subsets will be analyzed by flow cytometry. Data are analyzed with ANOVA with repeated measures.

Eligibility Criteria:
Inclusion Criteria:

* All patients who are eligible for Ocrelizumab therapy based on FDA criteria

Exclusion Criteria:

* All patients who are ineligible for Ocrelizumab therapy based on FDA criteria.
* Prior treatment with Alemtuzumab or stem cell therapy, or immune abnormalities that would interfere with planned tests.
* Hepatitis B and HIV infections.
* Pregnant or lactating women.
* Hypersensitivity to trial medications.
Cognitive Motor Dual Task Versus Task Specific Training on Cognition and Motor Functioning in Stroke Patients

This study focuses on Dual Task Training as daily living involves many dual task conditions, in which a person requires to do two or more tasks at same time. without the ability to carry out these types of Dual movements. This study aims to improve the ability to do two tasks at same time, targeted to decrease the risk of fall in stroke patients. This study helps in understanding how multiple tasks simultaneously affects patients' abilities and creating effectiveness programs.

The World Health Organization (WHO) defines the stroke as a brain injury that causes rapid and noticeable changes in cerebral function, lasting 24 hours or longer, or resulting in death. Strokes can be caused by vascular issues and include cerebral infarction, intracerebral hemorrhage, and subarachnoid hemorrhage. Stroke is a syndrome characterized by acute neurological deficits caused by vascular injury in the central nervous system. It's a major cause of disability and mortality globally, resulting from various risk factors, diseases, and mechanisms. Dual-task training refers to the ability to simultaneously perform multiple cognitive and motor activities while maintaining postural control. Divided attention is the capacity to do more than one thing at the same time. Dual-task training innovatively combines motor and cognitive rehabilitation in a comprehensive module. TST, or task-specific training, is a popular rehab approach that emphasizes function and is commonly used for stroke patients. It's all about targeting specific tasks to help with recovery.

RCT conducted on two groups, Dual Task Training and Task Specific training. interventions applied with a frequency of three times a week for eight weeks protocol. Participants will be divided into 2 groups. 1st group will receive Dual task training for motor and cognition simultaneously. 2nd group will receive task specific training for motor and cognition functioning.

Eligibility Criteria:
Inclusion Criteria:

* Patients with age ≥ 45 years' old both male and female.
* Patients with Mild cognitive impairment with MOCA score of 18-25.
* Patients with sub-acute or chronic stage of stroke and are able to sit
* independently for 30 secs.
* Patients with primary level education.

Exclusion Criteria:

* Patients with dementia that had been diagnosed by a neurologist.
* Patients with neurological, psychiatric, or medical disorders.
* Patients with auditory or visual impairments.
Outcome of Laser or Debrider Tonsillotomy Versus Tonsillectomy in Obstructive Sleep Apnea

Tonsil surgery for children suffering from obstructive sleep apnea have significant post operative morbidity including pain and occasionally bleeding. This morbidity is partly caused by post surgical inflammation. This inflammatory process can be quantified using various proinflammatory cytokines.

the goal of this study is to objectively compare the inflammatory process after treatment of obstructive sleep apnea with different surgical approaches to the enlarged tonsils.

Tonsil surgery for children suffering from obstructive sleep apnea have significant post operative morbidity including pain and occasionally bleeding. This morbidity is partly caused by post surgical inflammation. This inflammatory process can be quantified using various proinflammatory cytokines.

the goal of this study is to objectively compare the inflammatory process after treatment of obstructive sleep apnea with different surgical approaches to the enlarged tonsils.

In the study three approaches are prospectively compared:

1. Tonsillectomy - using electrocautery resecting all tonsillar tissue.
2. Debrider Tonsillotomy - reducing the tonsillar tissue with a debrider.
3. laser Tonsillotomy - reducing tonsillar tissue using a CO2 laser.

All patients will be randomized to one of three arms. Each arm will include 25 children.

All children will have a preoperative and postoperative sleep study. Questioners assessing pain, amount of medication used to control pain and sleep disturbance during the first 7 days after surgery will be filled by the child caretaker.

Blood will be drawn immediately before surgery and 18-24 hours after surgery. The following blood products will be assessed: White blood cells, clotting factors, C reactive protein, IL1 beta,TNF alpha, IL6, IL2.

If the study will show objectively and subjectively that partial resection of the tonsil compared to complete tonsillectomy is less painful and has less postoperative inflammation.

Eligibility Criteria:
Inclusion Criteria:

age 2-16 obstructive sleep apnea AHI\>5 Hypertrophy of tonsils and adenoids

-

Exclusion Criteria:

Children with recurrent tonsillitis craniofacial anomalies Neuromuscular disease Down syndrome
Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer

This trial studies the barriers associated with timely chemotherapy given after surgery (adjuvant) in patients with invasive breast cancer. Meeting with patients and asking questions may help doctors to learn about factors that can cause delays in the start of chemotherapy after surgery in patients with breast cancer.

PRIMARY OBJECTIVES:

I. To comprehensively and qualitatively assess and identify the determinants of time to chemotherapy (TTC) delays in a vulnerable population using qualitative methods.

Ia. To describe the health literacy/numeracy, social support and level of trust in physicians of the study participants. (Exploratory)

OUTLINE:

Patients complete questionnaires and participate in an interview to answer questions about the information patients received before starting the chemotherapy, any medical problems after the surgery that could have been related to the start of the chemotherapy, how the chemotherapy affected patients' life, and anything else patients may remember between the time when the breast surgery ended and the first dose of chemotherapy started. Patients' medical records are also reviewed.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with primary invasive breast cancer
* For patients receiving adjuvant chemotherapy: First dose of chemotherapy administered \>= 60 days after definitive breast cancer surgery. For patient treated with neoadjuvant chemotherapy: First dose of chemotherapy administered \>= 60 days after pathological diagnosis
* Diagnosis of breast cancer within three years of study enrollment
* Can speak, read, and understand English and/or Spanish
* Patient of Lyndon B. Johnson General Hospital-Harris Health System (LBJ-HHS) or MD Anderson Cancer Center

Exclusion Criteria:

* Women hospitalized for a critical condition or who are considered medically unstable by their medical team
* Patients that started chemotherapy \>= 3 years after definitive breast cancer surgery
Effect Dietary Fibre Supplementation on Gut Microbiota Composition

The study involves taking pectin fibre at increasing doses ranging from 5g, 10g and 15g for a total period of 6 weeks with the increase every 2 weeks. Study subjects will be healthy volunteers recruited from the University and local population and will be asked to attend the laboratory on 4 occasions; at the start of the intervention and every 2 weeks, at the end of each dosing period. At each study visit (\~3hrs), participants will be asked to provide a stool and blood sample and will have blood pressure measured. In the week before each study visit, participants will record their food intake.

The study aims to assess the optimal dosage of pectin required to see beneficial effects on inflammation and gut microbiome composition. 15 healthy, non-obese volunteers will be recruited following a successful medical screening. Between recruitment and first study visit, and at the end of each dosing period (before each study visit), participants will be asked to complete a dietary record (4 days), to collect a stool sample on the day before the study visit and to fast from midnight the night before this visit.

At both study visits, participants will have weight, hip/waist circumference and blood pressure measured. They will be asked to complete some questionnaires. After completion of the first study day, participants will be provided with the required dosage of pectin for the 2-week dosing period. They will be given the required doses of pectin portioned in individual sachets, with instructions to add the contents of one sachet a day to juice, smoothies or water and to consume immediately. Study visits will be scheduled at the end of every 2-weeks.

Eligibility Criteria:
Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the study
* Participant eligibility includes those aged \>18 years who have a body mass index (BMI) between 18.5 and 39.9 kg/m2

Exclusion Criteria:

* Have psychosocial or gastrointestinal (e.g. malabsorptive conditions such as IBS/IBD, coeliac)
* Are taking the following medications: immunosuppressants, anti-histamines, amiodarone and/or perhexiline
* Are currently following or anticipated to commence a specialised commercially available weight loss diet and/or program/ taking prebiotic supplements
* Pregnant or breast feeding
* History or current psychiatric illness
* History or current neurological condition (e.g. epilepsy)
* Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance